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Abstract: 
Malaria remains a life-threatening disease with significant public health implications, especially in 
Sub-Saharan Africa. Malaria can be detected early, which can lead to earlier care and a reduction in 
morbidity and disease burden. Researchers in Owerri, Nigeria, decided to learn more about 
subclinical malaria symptoms. The study took place in two communities: Naze and Ikenegbu, both of 
which are suburbs of Owerri metropolis, between September and December. Using a home, 
systematic sampling process, 468 people were drawn for the study from both locations, with males 
196 (41.9%) and females 272 (58.1%) meeting the inclusion criteria. A positive microscopy result 
for the malaria parasite was needed for inclusion, but there were no typical clinical symptoms. Later, 
the participants were given Artemether Lumefantrine. The most common symptoms of subclinical 
malaria reported by the participants were body itching (444, 94.9 percent), bone pain (440, 94.0 
percent), sleepiness (440, 94.0 percent), bad dreams (428, 91.4 percent), and dizziness (440, 94.0 
percent). 368 (78.6%), bitter/sour taste 360 (76.9%), joints/muscular pains 308 (65.8%), and body 
exhaustion 300 are the most common complaints (64.1 percent ). The most common signs are 
cough/catarrh, 92 (2.7 percent), and stomach pain, 92 (2.7 percent) (19.7 percent), yellow urine (6.0 
percent), constipation (6.0 percent), and sleeplessness (20 percent) (4.3 percent ). The numbers 
observed increased as a result of the fact that many people identified more than one symptom. These 
subclinical symptoms increase the risk of impending malaria attacks, causing patients to seek prompt 
diagnosis and treatment. Artemether-lumefantrine started in the subclinical stage had a better 
treatment outcome than artemether-lumefantrine started in the clinical stage, when the most 
debilitating features of the malaria attack surface, according to a recent study in the same research 
region. Malaria could be reduced in morbidity, mortality, and socioeconomic burden if it is detected 
and treated early. 
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1. INTRODUCTION 
Despite significant progress in reducing the number of malaria cases and deaths worldwide, malaria 
remains a life-threatening disease with significant public health implications in the world today, 
especially in Sub-Saharan Africa. According to the World Health Organization's (WHO) most recent 
global survey, there were 214 million cases of malaria in 2015, 438,000 deaths worldwide, and about 
3.2 billion people – almost half of the world's population – were at risk of malaria in 2015. 
Malaria is caused by the infestation of red blood cells with protozoan parasites of the genus 
plasmodium inoculated into the human host by a feeding female anopheline mosquito. The four 
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human Plasmodium species transmitted from person to person are P. falciparum, P. vivax, P. ovale, 
and P. malaria. Increasingly human infestations with the monkey malaria parasite, P. knowlesi are 
being reported from the forested region of South-East Asia and particularly the Island of Borneo  
The classic symptom of malaria is paroxysm—a cyclical occurrence of sudden coldness followed by 
shivering and then fever and sweating, occurring every two days (tertian fever) in P. vivax and P. 
ovale infections, and every three days (quartan fever) for P. malariae. P. falciparum infection can 
cause recurrent fever every 36–48 hours, or a less pronounced and almost continuous fever  
At the subclinical stage of the disease, there are initial manifestations that are common to all malaria 
species and are similar to flu-like symptoms.. These symptoms are non-specific and can resemble 
other conditions such as sepsis, gastroenteritis, and viral diseases.  They comprise lassitude, fatigue, 
abdominal discomfort, and muscle and joint aches. Others may include bone pain, bad dreams, bitter 
taste, retrograde amnesia, hypothermia, pruritus on cold bath, and restlessness. The later presentation 
may include headache, fever, shivering, joint pain, vomiting, and hemolytic anemia, and jaundice, 
hemoglobin in the urine, retinal damage, and convulsions 
In a study to investigate where a key stage of the lifecycle of malaria parasite takes place Joice et al 
looked at tissue samples from autopsies of children who had died from malaria. This interesting 
study found evidence of the likelihood that the sexual reproductive stage in the lifecycle of 
Plasmodium falciparum takes place outside of the blood vessels, in the bone marrow. It has also 
shown that these immature gametocytes are rarely destroyed by the immune system and this might 
explain the manifestation of bone pains at the subclinical stage of the disease. 
In the study area, a literature search could not show any study that has been done to establish some of 
these symptoms. Identification and establishment of the symptoms and signs which present at the 
early stage of the disease can serve as warning signals and thus help the patient to seek medical 
diagnosis and treatment quite early. These can as well raise the index of suspicion of the medical 
personnel aiding early management of malaria. Treatment at this early stage of the disease when it is 
little or no organ dysfunction usually leads to full recovery and stalls progression to lethal severe 
malaria especially in the case of P. falciparum.  
Consequently, the burden of malaria can be minimized by a reduction in mortality and morbidity 
rate, reduction in the direct and indirect cost of treatment of malaria. A recent study done in the same 
study area showed a better treatment outcome with artemether-Lumefantrine initiated at the 
subclinical stage than during the clinical stage. Therefore, this study aimed at establishing some of 
the major symptoms associated with subclinical malaria in Owerri, South Eastern Nigeria. 
2. MATERIALS AND METHOD  
2.1  STUDY AREA 
Owerri is Nigeria's administrative capital of the state of Imo. It is also the largest state city, the 
second and third being followed by Orlu and Okigwe. Owerri consists of three Local Government 
Areas, namely Municipal Owerri, North Owerri and West Owerri, with co-ordinates 50 4 8 50N 70 3 
50 N. As of 2016, the population is estimated to be about 1,401,873 and the town is about 100 square 
kilometers (40 sq mi). Owerri is bordered by the Otamiri River to the east and the Nworie River to 
the south. To represent semi-urban and urban areas, respectively, Naze and Ikenegbu were selected. 
The normal temperature is 26.40C, whereas the average precipitation is 2,219 mm. For the rainy 
season (April to September) and for the dry season (October to March), the annual rainfall is 214 to 
220 cm. It is a malaria-endemic area, with other species predominating in P.falciparum  
 
2.2  STUDY POPULATION AND SAMPLING 
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The study population consisted of males and females aged 18 years and above who were living in the 
study areas at the period of study. The study lasted for 4 months. After thorough house mapping and 
numbering of houses in these communities, a systematic house-to-house sampling technique was 
employed in the selection of the participants who fulfilled the inclusion criteria.  
The inclusion criteria were; subjects that claimed they can recognize subclinical malaria symptoms 
and confirmed they had the symptoms at the time of the survey and who tested positive for 
Plasmodium falciparum malaria detected by microscopy. Other criteria used for inclusion were the 
absence of clinical malaria symptoms or signs especially fever, headache, chills, or rigor; ability to 
swallow and tolerate the oral medication (Coartem); ability and willingness to give consent and to 
comply with the protocol for the duration of the study as well as comply with the study visit 
schedule. Also not included were subjects who treated malaria within two weeks before the study 
and/ or were pregnant/lactating mothers.  
2.3  STUDY DESIGN AND DATA COLLECTION 
This study utilized a community-based, interventional study in two different communities in Owerri, 
Southeastern Nigeria. A carefully prepared and face validated questionnaire was used to elicit 
information from participants. Screening of participants in the field was achieved using the 
questionnaire and the Carestat RDTs.  
2.4  LABORATORY EXAMINATION AND SCREENNING  
Carefully prepared slides were screened microscopically in the laboratory under x 100 oil immersion 
lens using a light microscope as a confirmatory test. Parasite density was determined with the thick 
films by counting the number of asexual parasites per 200 white blood cells (WBC) and calculated 
per µL. The absence of malaria parasite in 100 high power ocular fields of the thick film was 
considered as negative. Detection of the parasites species was done with thin films. Participants who 
had subclinical malaria were treated with Coartem by one of the researchers who are a medical 
doctor. The drugs were administered according to the manufacturer's recommendations, and they 
were subsequently followed up to ensure a full recovery.  
2.5  DATA ANALYSIS 
As the prevalence of subclinical malaria in the study area was yet unknown, prevalence was assumed 
at 50% (0.5). So using the formula: z2x P (1-P)/q2where z= 1.96 at 95% confidence interval, P 
(Prevalence of subclinical malaria in the study area) = 0.5, q (margin of error) at 5%= 0.05, n= 
(1.96)2 x 0.5(1- 0.5) / 0.052 = 384. Consequently, a total of 468 participants were recruited from both 
sites (the urban and semi-urban communities). 
2.6  ETHICAL CONSIDERATION 
Ethical approval for this study was approved and obtained from the ethics committee of the Public 
Health Department, the Federal University of Technology Owerri School of Health (FUTO) and the 
Federal Medical Center (FMC) (Protocol No. 9789). The participants were informed of the goals, 
told of the confidentiality of the study and when they agreed to take part in the study, and were asked 
to sign an agreement of informed written consent and a follow-up case form. 
RESULTS 
Sociodemographic Characteristics of Participants:  
A total of 468 participants were recruited for the study, 204 (43.6%) from the suburban community 
(Naze), 264 (56.4%) from the urban community (Ikenegbu) in Owerri Imo State Nigeria.  One 
hundred and ninety-six (41.9%) of them were male while 272 (58.1%) were female (Table 1). 
Out of the 468 participants, 168 (35.9%) were between the ages of 18-22, 52 (11.1%) between 23-27 
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years of age, 76 (16.2%) between 28-32years while 52(11.1%), 24(5.1%) and 96 (20.5%) were 
between the ages of 33-37, 38-42 and ≥43 years respectively (Table 1). The mean age was 32 years 
in both study areas.
 
In the area of occupation of the participants, the majority, 34(29.1%) were students, 30(25.6%) were 
civil/public servants, 30(25.6%) were businessmen/women whereas 19(16.2%) and 4(3.4%) were 
farmers and unemployed respectively.  At the suburban study community (Naze), the majority of the 
participants, 68 (33.3%) were farmers while at Ikenegbu (urban community), the majority of the 
participants, 88 (33.3%) were businessmen or women (Table 1) 
Major Subclinical Malaria Symptoms Reported by Participants in Owerri, Imo State 
The major symptoms of subclinical malaria reported by the participants from both study sites 
included body itching, 444 (94.9%), bone pains and sleeplessness,  440 (94.6%) each, 440 (12.8%), 
bad dreams, 428 (91.4), dizziness, 368 (78.6%), bitter/sour taste, 360 (76.9%), joints/muscular pains, 
308 (65.8%), and weakness of the body, 300 (64.1). Others reported were cough/catarrh, abdominal 
discomfort, and loss of appetite, all of which were 92 (19.7%) each, yellow urine, 28 (6.0%), 
constipation, 28 (6.0%), and sleeplessness, 20 (4.3%) (Table2). 
At the suburban community of study (Naze), the order of frequency of the major symptoms of 
clinical malaria varied with bad dreams topping the others, 196 (96.1%), followed by sleepiness and 
body itching, 192 (94.1%) each, bone pain, 184 (90.2%), bitter/sour taste, 172 (84.3%), 
joint/muscular pain, 124 (60.8%), weakness of the body, 88 (43.%) and others, 144 (70.2%).  At 
Ikenegbu (the urban community of study), bone pain was highest, 256 (96.7%), followed by body 
itching, 252 (95.5%), sleepiness, 248 (93.9%), bad dreams, 232 (87.9%), dizziness, 220 (83.3%), 
weakness of the body, 212 (80%), bitter/sour taste, 188 (71.2%), joint/muscular pain, 184 (69.7%), 
and others 208 (78.8%) (Table 2) 
Table 1: Sociodemographic Characteristics of Participants 
Variables                                           Naze                              Ikenegbu                       Total 
                                                         No. (%)                            No. (%)                       No. (%) 
Sex 
         Male                                    104(51.0)                           92(34.8)                    196(41.9) 
        Female                                  100(49.0)                            172(63.2)                  272(58.1)                    
        Total                                    204(100.0)                           264(100.0)                468(100.0) 
Age     
         18- 22                                  68 (33.3)                              100(37.9)                  168(35.9) 
           23-27                                 20(9.8)                           32(12.1)                     52(11.1) 
           28-32                                 24(11.8)                           52(19.7)                     76(16.2) 
           33-37                                 16(7.8)                                 36(13.6)                      52(11.1) 
           38-42                                 12(5.9)                           12(4.5)                        24(5.1) 
           ≥43                                    64(31.4)                               32(12.1)                       96(20.5) 
          Total                               204(100.0)                             264(100.0)                   468(100.0) 
Occupation 
  Civil/Public Service                 36(17.6)                                 84(31.8)                     120(25.6) 
   Business                                  32(15.7)                                 88(33.3)                     120(25.6) 
   Studying                                56(27.5)                                  80(30.3)                      136(29.1) 
   Farming                                 68(33.3)                                   8(3.0)                         76(16.2) 
   Unemployed                          12(5.9)                                     4(1.5)                         16(3.4) 
   Total                                  204(100.0)                                  264(100)                    468(100.0) 
Location                                   51(43.6) N                              66(56.4) I            117(100.0)  
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Table 2: Major Symptoms of Subclinical Malaria Enlisted by 468 Participants 
In Owerri Imo State 
Major Symptoms of 
Subclinical Malaria 
                  Locations 
Naze No.(%)       Ikenegbu No.(%)         Total No.(%) 
 Bone pain 184(90.2)                256 (96.7)                        440 (94.0)                                                                    
 Joint/muscular pains 124(41.1)                184(69.7)                         308 (65.8)                                                                                
 Body Weakness    88(41.3)               212(80.3)                         300(64.1)                                                                           
 Bad dreams 196(96.1)                232(87.8)                         428(91.4)                                                                        
 Dizziness 148(74.0)                220(83.3)                         368(78.6)                                                       
 Bitter/sour taste
 172(84.3)                188(71.2)                         360(76.9)                                                           
 Sleepiness 192(94.1)                248(93.9)                         440(94.0)                                                         
 Body itching 192(94.1)                252(95.5)                         444(94.9)                                   
 Cough/catarrh, 
Abdominal                            
discomfort                                                    
Loss of appetite,  
Yellow urine                                                                                          
 
Constipation                                                               
 
Sleeplessness                                                                                                            
  30(14.7)                 62( 23.5                           92 (19.7)                                                                                                                                    
   42(22.8)                 50(19.5)                          92 (19.7) 
37(18.1)             55(20.8)                          92 (19.7) 
   17 (8.2)                 11(4.2)                             28 (6.0)  
   13(6.4) 15(5.7)           28 (6.0)                                                            
    9(4.4)                   11(4.2)                             20 (4.3) 
 
N.B. There were multiple responses from participants; some indicated more than one subclinical 
symptom. 
Discussion: 
The major symptoms of subclinical malaria established from this study in decreasing order of 
frequency included body itching, bone pains, sleepiness, bad dreams, dizziness, bitter/sour taste, 
joints/muscular pains, and weakness of the body. Few others reported constipation, abdominal 
discomfort, and loss of appetite, yellow urine, cough/catarrh, and sleeplessness. This was similar to 
earlier findings which had identified some of the above-mentioned symptoms (weakness of the body, 
abdominal discomfort, Muscular/joint pains) and bone pains to occur at the early stage of malaria. 
Others like bad dreams, dizziness, and bitter/sour taste, and sleepiness, sleeplessness have thus been 
established by this study. 
 
These symptoms create suspicion of impending malaria attacks among individuals. Information 
deduced from the participants showed that many of them could predict subclinical malaria disease 
following the experience of these symptoms. This could cause them to take further actions towards 
proper diagnosis and treatment at the early stage. 
At this early stage of disease progression, with mild or no vital organ dysfunction, a rapid, full 
recovery is expected, provided prompt, effective antimalarial treatment is given. If ineffective or 
poor quality medicines are given or if treatment is delayed, particularly in P. falciparum malaria, the 
parasite burden often continues to increase and the patient may develop potentially lethal severe 
malaria. Symptoms like yellowing of urine and weakness of body become more pronounced in 
clinical cases when the fever had already set in and breaking off more blood cells by the parasite 
becomes pronounced leading to clogging of blood vessels by antigen/antibody complexes. 
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Early detection and treatment of malaria have been known not only to prevent progression to severe 
form of malaria but also to reduce morbidity and mortality and burden of disease in terms of cost of 
treatment and prolonged hospital stay as well as absenteeism from work/school. Also, the subclinical 
symptoms established in this study will raise a high index of suspicion among medical personnel as 
these patients present to them for diagnosis and treatment.  
The study was able to establish some more symptoms associated with subclinical malaria in the study 
sites which included; body itching, bone pain, sleepiness, bad dreams, and bitter/sour taste. These 
symptoms serve as alert to both patients and medical personnel prompting them towards early 
diagnosis and proper treatment which in turn will reduce the morbidity and mortality rates of malaria 
in affected areas.  
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